Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines and clinical practice, the authors said.
[4] [5] The most commonly reported adverse effects of semaglutide are gastrointestinal in nature, reflecting its mechanism of action on the digestive system
May 4, 2025: New study suggests more adverse events associated with compounded GLP-1s than standard formulations Major Stories New research shows a correlation between compounded weight loss and diabetes injectables and increased adverse events
Making better food choices, staying active, getting enough sleep, managing stress, and addressing any health conditions all play important roles alongside your treatment
Sermorelin improves metabolism and promotes healthier skin because of the enhancement of the body's natural production of GH